Jonathan Krell

Jonathan Krell

Auto-generated profile, based on publicly available information

Jonathan Krell

Institute of Reproductive and Developmental Biology

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
TGTamara M. H. Gall
Tamara M. H. Gall
JJJimmy Jacob
Jimmy Jacob
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
JKJonathan Krell
Jonathan Krell
CKCharis Kyriakides
Charis Kyriakides
LJLong R. Jiao
Long R. Jiao
Circulating tumor cells (CTCs) disseminate from the primary tumor and travel through the bloodstream and lymphatic system. The detection of and/or increase in the number of CTCs during a patient’s clinical course may be a harbinger of forthcoming overt metastasis. We aimed to examine the impact of 2 different surgical techniques, standard (ST) pancreaticoduodenectomy (PD) and no-touch isolation (NT) PD, on tumor behavior and outcome in patients with pancreatic cancer by using CTCs as biomarkers. In this pilot study, patients were randomized to either ST-PD (n = 6) or NT-PD (n = 6). Intraoperatively, blood samples were taken from the portal vein for measurement of CTCs before and immediately after removal of the tumor. An increase in CTCs was seen in 5 of 6 patients (83%) with ST-PD but no patients with NT-PD (P = .003). In the ST-PD and NT-PD groups, median overall survival was 13.0 and 16.7 months, respectively (P = .33); there was no difference in disease-free survival (P = .42). The use of NT-PD significantly reduced the number of CTCs in the portal vein with no benefit in survival outcomes compared with ST-PD, although more extensive studies are required.

7 December 2022 in Polymer Chemistry
Verified
Journal Article
Open access
PDF file
JCJoana S. Correia
Joana S. Correia
SMSofía Mirón-Barroso
Sofía Mirón-Barroso
CHCharlotte Hutchings
Charlotte Hutchings
Silvia OttavianiSilvia Ottaviani
Silvia Ottaviani
BSBirsen Somuncuoğlu
Birsen Somuncuoğlu
Theoni GeorgiouTheoni Georgiou
Theoni Georgiou
Effect of the position of the cationic charges on the polymer chains on cytotoxicity.

22 May 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
PCPaula Cunnea
Paula Cunnea
ECEdward W. Curry
Edward W. Curry
ECElizabeth L Christie
Elizabeth L Christie
KNKatherine Nixon
Katherine Nixon
CKChun Hei Kwok
Chun Hei Kwok
CFChristina Fotopoulou
Christina Fotopoulou
Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor simpler sympodial evolution. Three distinct tumor evolutionary patterns from primary to relapse are identified, demonstrating recurrent disease may emerge from pre-existing or newly detected clones. Crucially, we identify spatial heterogeneity for clinically actionable homologous recombination deficiency scores and for poor prognosis biomarkers CCNE1 and MYC. Copy-number signature, phenotypic, proteomic, and proliferative-index heterogeneity further highlight HGSOC complexity. This study explores HGSOC evolution and dissemination across space and time, its impact on optimal surgical cytoreductive effort and clinical outcomes, and its consequences for clinical decision-making.

17 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
NMNabeel Merali
Nabeel Merali
TCTarak Chouari
Tarak Chouari
Kayani KayaniKayani Kayani
Kayani Kayani
CRCharles Rayner
Charles Rayner
JJJose Jimenez
Jose Jimenez
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second most common cause of cancer death in the USA by 2030, yet progress continues to lag behind that of other cancers, with only 9% of patients surviving beyond 5 years. Long-term survivorship of PDAC and improving survival has, until recently, escaped our understanding. One recent frontier in the cancer field is the microbiome. The microbiome collectively refers to the extensive community of bacteria and fungi that colonise us. It is estimated that there is one to ten prokaryotic cells for each human somatic cell, yet, the significance of this community in health and disease has, until recently, been overlooked. This review examines the role of the microbiome in PDAC and how it may alter survival outcomes. We evaluate the possibility of employing microbiomic signatures as biomarkers of PDAC. Ultimately this review analyses whether the microbiome may be amenable to targeting and consequently altering the natural history of PDAC.

9 January 2013 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
TGTamara Mh Gall
Tamara Mh Gall
Leandro CastellanoLeandro Castellano
Leandro Castellano
JSJustin Stebbing
Justin Stebbing
LJLong R Jiao
Long R Jiao
JKJonathan Krell
Jonathan Krell
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, despite advances in imaging, surgery and a greater understanding of its molecular biology. Patient outcomes remain poor due to an inability to detect disease early and resistance to anticancer treatments. miRNAs are promised to become ideal cancer biomarkers, as they are tumor and tissue specific and also incredibly stable molecules. So far, large profiling studies of the PDAC miRNome have identified the 'usual suspects' known to be deregulated in solid tumors, such as oncomiR-21, as well as others that could be more robust for differentiating malignant from benign pancreatic disease. However, many of these are yet to be validated clinically. The paper under evaluation provides further evidence for the use of miRNAs as diagnostic biomarkers for PDAC. We have reviewed the use of miRNAs as diagnostic analytes for detecting PDAC in biopsies.

1 November 2023 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
BHBenjamin H. L. Harris
Benjamin H. L. Harris
CMCaitlin McCabe
Caitlin McCabe
HSHana Shafique
Hana Shafique
SLSimon Lammy
Simon Lammy
LTLaura Tookman
Laura Tookman
JKJonathan Krell
Jonathan Krell
Genetic testing is becoming rapidly more accessible to the general populous either through or outside healthcare systems. Few large-scale studies have been carried out to gauge public opinion in this growing area. Here, we undertook the largest cross-sectional study on genetic testing in the UK. The primary purpose of this study is to identify the differences in attitudes toward genetic testing across ethnic groups. A cohort of 6500 individuals from a diverse population completed a 72-item survey in a cross-sectional study. Responses between ethnic minority and white individuals in the UK were compared using a wilcoxon rank-sum and chi-square tests. The white cohort was approximately twice as likely to have taken a genetic test and 13% more had heard about genetic testing before the survey. The ethnic minority cohort appeared more apprehensive about the impact of genetic testing on employability. This study highlights that in the UK, significant differences in opinions regarding genetic testing exist between white individuals and ethnic minority individuals. There is an urgent need to develop more inclusive strategies to equally inform individuals from all backgrounds to avoid disparities in the utilisation of genetic testing.